• Candidatures for WinningNormandy research training network

    Our laboratory is welcoming applications from ambitious junior researchers with at least 4 years of research experience (including PhD studies) to apply for the competitive research funding from the postdoctoral research training network  The WINNINGNormandy Fellowship Programme | Région Normandie

    Our laboratory is offering potential candidates a unique research environment, including  long-standing expertise in functional in vivo and ex vivo cardiovascular evaluations and access to our wide panel of relevant experimental models of cardiovascular diseases ranging from myocardial infarction, ischemia-reperfusion injury, chronic heart failure, acute heart failure, metabolic syndrome-induced cardiomyopathy, chronic kidney-disease induced cardiomyopathy, and sepsis-induced cardiomyopathy. Please contact our lead PIs for more details:

    Paulus Mulder (expertise in HF models) paul.mulder[at]univ-rouen.fr ORCID

    Ebba Brakenhielm (expertise in cardiac lymphatics) ebba.brakenhielm[at]univ-rouen.fr ORCID

    Jeremy Bellien (expertise in endothelial dysfunction) jeremy.bellien[at]univ-rouen.fr ORCID

    Read more

  • sEH blockade prevents cardiorenal syndrome

    A recent experimental study, directed by D Guerrout, published in Front Mol Biosci , describes the beneficial cardiac impact, on both diastolic and systolic functions, of blocking soluble epoxide hydrolase (sEH) during chronic kidney disease (CKD) induced by 5/6 nephrectomy (Nx) in mice. These beneficial effects may be mediated by the prevention of endothelial dysfunction, independent from kidney preservation and antihypertensor effect. Thus, inhibition of sEH holds a therapeutic potential in preventing type 4 cardiorenal syndrome.

    Read more

  • Finerenone beneficial impact in ovariectomized mice

    A recent study, directed by A Ouvrard-Pascaud, published in ESC Heart Failure describes the beneficial impact of Mineralocorticoid receptor blockade, with finerenone, on cardiac function and exercise capacity in ovariectomized mice. Briefly, the authors evaluated whether the non-steroidal mineralocorticoid receptor antagonist finerenone limited the progression of heart failure in ovariectomized (OVX) mice with metabolic disorders. They found that Finerenone improved mitochondrial ATP production in OVX mice. In addition, weight gain, increased blood pressure, and decreased insulin and glucose tolerance developing in OVX mice were improved by finerenone. The exercise capacity was diminished in untreated OVX mice and improved with Finerenone.

    Read more

  • BioArt 2020 winner

    Coraline Heron, a 1st year PhD student in the laboratory, has together with our collaborator, David Godefroy (Inserm U1239), used light sheet imaging to reveal the delicate network of cardiac lymphatics in mice. Their work was awarded with a 1st Prize at the yearly FASEB BioArts competition in 2020.


    Read more

  • Use of RAS inhibitors in patients with COVID-19

    Some concerns about the prescription of drugs acting on the renin-angiotensin system (RAS) have emerged due to SARS COV2 and COVID-19 pandemic and the revelation of the fundamental role of ACE2 (angiotensin-converting enzyme 2) in COVID-19 infection. Indeed, SARS COV2 utilizes ACE2 as a membrane receptor to enter target cells. Consequently, the question arises whether RAS modulating drugs impact the risk of developing severe or fatal severe acute respiratory syndrome in case of COVID-19 infection.  Here we discuss the evidence avilable on the impact of angiotensin-converting enzyme 1 inhibitors (ACEi) versus angiotensin II type 1 receptor blockers (ARB). Based on the currently available evidences, and as recommended by several medical societies, ACEi or ARB should not be systematically discontinued because to date no safety signal was raised with the use of these drugs.

    Alexandre J, Cracowski JL, Richard V, Bouhanick B; French Society of Pharmacology and Therapeutics (SFPT). Drugs acting on renin angiotensin system and use in ill patients with COVID-19. Therapie. 2020;75(4):319-325.

    doi: 10.1016/j.therap.2020.05.009.. PMID: 32553503

    Read more

Inserm U1096


Research performed in Inserm U1096 Unit in Rouen, concerns evaluation of the mechanisms behind and novel treatments of cardiovascular diseases, focusing on vascular protection and improvement of cardiac contractile function. This research is transversal, and performed both in experimental models and in human.

Vascular research: 

Our work mostly concerns the protection of vascular endothelial cells in the context of cardiovascular risk factors or cardiovascular diseases (hypertension, diabetes, myocardial infarction, heart failure etc. ). We also investigate new biotherapy approaches for stimulation of cardiac angiogenesis and lymphangiogenesis.

Cardiac research:

Development and assessment of new treatments of heart failure, as well as the clinical evaluation of percutaneous aortic valve replacement.


Endothelium, Valvulopathy
& Heart Failure

Réalisation Internet Bordeaux LOGO internet bordeaux mini

Contact Us

Legal mentions